Boston Partners Grows Position in Biogen Inc (BIIB)

Boston Partners lifted its stake in Biogen Inc (NASDAQ:BIIB) by 2.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 176,007 shares of the biotechnology company’s stock after buying an additional 3,920 shares during the period. Boston Partners owned about 0.09% of Biogen worth $52,964,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BIIB. Portfolio Solutions LLC bought a new stake in shares of Biogen in the fourth quarter valued at about $26,000. IMS Capital Management bought a new stake in shares of Biogen in the third quarter valued at about $38,000. Jackson Grant Investment Advisers Inc. bought a new stake in shares of Biogen in the fourth quarter valued at about $40,000. Moody National Bank Trust Division bought a new stake in shares of Biogen in the fourth quarter valued at about $41,000. Finally, Oregon Public Employees Retirement Fund lifted its stake in shares of Biogen by 27,620.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 14,309,047 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 14,257,427 shares during the period. Institutional investors and hedge funds own 88.94% of the company’s stock.

NASDAQ:BIIB opened at $321.17 on Friday. Biogen Inc has a 1 year low of $249.17 and a 1 year high of $388.67. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.32 and a quick ratio of 2.04. The company has a market capitalization of $65.93 billion, a PE ratio of 12.77, a PEG ratio of 1.18 and a beta of 1.13.

Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, January 29th. The biotechnology company reported $6.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.72 by $0.27. Biogen had a net margin of 32.94% and a return on equity of 40.53%. The company had revenue of $3.53 billion during the quarter, compared to analysts’ expectations of $3.39 billion. During the same quarter in the previous year, the company posted $5.26 earnings per share. Biogen’s quarterly revenue was up 6.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Biogen Inc will post 28.68 EPS for the current year.

Several equities research analysts recently weighed in on BIIB shares. BidaskClub cut shares of Biogen from a “hold” rating to a “sell” rating in a research note on Saturday, October 27th. Oppenheimer set a $380.00 price target on shares of Biogen and gave the stock a “buy” rating in a research note on Sunday, October 28th. ValuEngine upgraded shares of Biogen from a “sell” rating to a “hold” rating in a research note on Tuesday, November 6th. Royal Bank of Canada cut their price target on shares of Biogen to $338.00 and set a “sector perform” rating for the company in a research note on Monday, November 26th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $400.00 price target on shares of Biogen in a research note on Wednesday, December 12th. Eight equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $376.28.

In other news, Director Alexander J. Denner bought 7,000 shares of the business’s stock in a transaction dated Friday, February 1st. The stock was bought at an average price of $328.45 per share, for a total transaction of $2,299,150.00. Following the completion of the purchase, the director now owns 10,909 shares of the company’s stock, valued at approximately $3,583,061.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alexander J. Denner bought 30,000 shares of the business’s stock in a transaction dated Wednesday, January 30th. The stock was purchased at an average price of $324.86 per share, with a total value of $9,745,800.00. Following the purchase, the director now directly owns 10,909 shares of the company’s stock, valued at approximately $3,543,897.74. The disclosure for this purchase can be found here. Insiders own 0.29% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2019/02/22/boston-partners-grows-position-in-biogen-inc-biib.html.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.

Featured Story: How does a reverse stock split work?

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit